Skip to main content
SpringerLink
Log in

Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis

A case control study

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

PURPOSE: A small group of patients with ulcerative colitis (UC) also suffer from primary sclerosing cholangitis (PSC). Genetic and immunologic differences exist between UC patients with and without concomitant PSC. Furthermore, UC patients with PSC are more prone to developing colonic dysplasia/aneuploidy compared with patients with UC only. Because colonic disease activity and treatment with sulfasalazine have been found to be of independent importance for development of colonic carcinoma in UC, this study aims to determine if differences exist concerning colonic disease activity in UC patients with and without PSC. METHODS: Twenty-nine PSC patients with total colitis were matched to two UC patients with total colitis but without liver disease. Case records and questionnaires were used to gain information on pharmacologic treatment and disease activity. RESULTS: Observation time was 20 (PSC group) and 23 years (UC only). Number of patients taking prophylactic treatment did not differ between groups. Patients with UC only had received treatment with systemic and local corticosteroids significantly more often than UC patients with PSC (P < 0.05 and P < 0.02). Patients with UC only were hospitalized because of colonic activity significantly more often (P < 0.02). Number of patients undergoing colectomy because of disease activity or number of patients with chronic continuous symptoms did not differ between the two groups. CONCLUSION: UC in patients with PSC runs a milder course than UC in patients without this complication, although the number of patients taking prophylactic treatment was the same. If lower disease activity reflects differences in pathogenesis of UC in patients with PSC or if it can explain increased risk to develop colonic malignancy in patients with both PSC and UC needs further elucidation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ 1955;2:1041–8.

    Google Scholar 

  2. Daniels GE. Psychiatric factors in ulcerative colitis. Gastroenterology 1948;10:59–62.

    Google Scholar 

  3. Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187–9.

    PubMed  Google Scholar 

  4. Riley SA, Mani VJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990;31:179–83.

    PubMed  Google Scholar 

  5. Olsson R, Danielsson A, JÄrnerot G,et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319–23.

    PubMed  Google Scholar 

  6. Broomé U, Glaumann H, Hellers G, Sörstad J, Nillson B, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow-up study in the county of Stockholm. Gut 1994;35:84–9.

    PubMed  Google Scholar 

  7. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;80:200–6.

    Google Scholar 

  8. Thorpe ME, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut 1967;8:435–48.

    PubMed  Google Scholar 

  9. Aadland E, Schrumpf E, Fausa O,et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655–64.

    PubMed  Google Scholar 

  10. Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982;17:187–91.

    PubMed  Google Scholar 

  11. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part IV. Carcinoma of the colon. Gut 1964;5:15–22.

    Google Scholar 

  12. Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877–80.

    PubMed  Google Scholar 

  13. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis-evidence for increased neoplastic potential. Hepatology 1995;22:1404–8.

    Article  PubMed  Google Scholar 

  14. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H-O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994;107:117–20.

    PubMed  Google Scholar 

  15. Chapman RW, Arborgh BA, Rhodes JM,et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980;21:870–7.

    PubMed  Google Scholar 

  16. Evans JG, Acheson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut 1965;6:311–24.

    PubMed  Google Scholar 

  17. Nordenvall B, Broström O, Berglund M, Monsén U, Sörstad J, Hellers G. Incidence of ulcerative colitis in Stockholm county 1955–1979. Scand J Gastroenterol 1985;20:311–24.

    Google Scholar 

  18. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiological study. Gut 1990;31:329–33.

    PubMed  Google Scholar 

  19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625–9.

    PubMed  Google Scholar 

  20. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumara M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–6.

    PubMed  Google Scholar 

  21. McFarlane IG. Autoreactivity against biliary tract antigens in primary biliary cirrhosis. Mol Aspects Med 1985;8:249–67.

    Article  PubMed  Google Scholar 

  22. Minuk GY, Angus M, Brickman CM,et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985;88:166–70.

    PubMed  Google Scholar 

  23. Zetterquist H, Broome U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992;33:942–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden

    Karin Lundqvist M.D. & Ulrika Broomé M.D., Ph.D.

Authors
  1. Karin Lundqvist M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrika Broomé M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by grants from Nanna Svartz Scholarship, Stockholm, Sweden.

About this article

Cite this article

Lundqvist, K., Broomé, U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis. Dis Colon Rectum 40, 451–456 (1997). https://doi.org/10.1007/BF02258391

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02258391

Key words

Search

Navigation